KEYNOTE-189
Regimen
- Experimental
- pembrolizumab + pemetrexed + platinum
- Control
- placebo + pemetrexed + platinum
Population
1L advanced non-sq NSCLC without EGFR/ALK alterations
Key finding
OS HR 0.49 (0.38-0.64); mOS 22.0 vs 10.7 mo; SoC for EGFR/ALK-WT 1L non-sq
Source: PMID 29658856
Timeline
- Enrollment start: 2016-01-15 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.182)
- CSCO NSCLC 2025 ⚠️ OCR source